Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Convatec GroupCHIX:CTECL +3.73%78 EV-to-EBIT is 25.65 as of Jul. 29, 2026, which is 20% below its 10-year median of 32.25. GuruFocus rates CHIX:CTECL with a GF Score™ of 78/100 and a GF Value™ of £2.57 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Convatec Group ranks worse than 67.74% on this metric.
The historical rank and industry rank for Convatec Group's EV-to-EBIT or its related term are showing as below:
CHIX:CTECl'
s EV-to-EBIT Range Over the Past 10 Years
Min: 16.1 Med: 32.25 Max: 82.18
Current: 25.65
During the past 13 years, the highest EV-to-EBIT of Convatec Group was 82.18. The lowest was 16.10. And the median was 32.25.
CHIX:CTECl's EV-to-EBIT is ranked worse than 67.74% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 18.695
vs CHIX:CTECl: 25.65
Convatec Group (CHIX:CTECl) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Convatec Group's Enterprise Value for the quarter that ended in Dec. 2025 was £5,823 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Convatec Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £216 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Convatec Group EV-to-EBIT Related Terms
Convatec Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Convatec Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CTECL vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Convatec Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Convatec Group EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Convatec Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Convatec Group's EV-to-EBIT falls into.
Convatec Group's current Enterprise Value is £5,551 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Convatec Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £216 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Convatec Group (CHIX:CTECL) has a EV-to-EBIT of 25.65 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Convatec Group and its competitors. This is 20% below median its historical median of 32.25. Over the past decade, Convatec Group's EV-to-EBIT has ranged from 16.10 to 82.18. According to the industry distribution chart, Convatec Group ranks #317 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 67.7%.
Is Convatec Group's EV-to-EBIT too high?
Convatec Group's current EV-to-EBIT of 25.65 is 20% below median its 10-year median of 32.25. Over the past 10 years, this metric has ranged from a low of 16.10 to a high of 82.18. The Medical Devices & Instruments industry median EV-to-EBIT is 18.70. Convatec Group's value of 25.65 is 37.2% above this industry median. Based on the distribution chart, Convatec Group ranks #317 out of 468 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Convatec Group has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Convatec Group ranks #317 out of 468 companies for EV-to-EBIT. This places Convatec Group in the lower half of its industry. The industry median EV-to-EBIT is 18.70. Convatec Group's value of 25.65 is 37.2% above this benchmark. Historically, Convatec Group's own EV-to-EBIT has ranged from 16.10 to 82.18 over the past decade. While the company's 10-year median is 32.25 vs. the industry median of 18.70, Convatec Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.70, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Convatec Group's current EV-to-EBIT of 25.65 is 37.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Convatec Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Convatec Group's current EV-to-EBIT is 25.65, which is 20% below median its own 10-year median of 32.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Based on GuruFocus' analysis, Convatec Group (CHIX:CTECL) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.57, compared to a current price of £2.28 — trading 11.2% below its estimated fair value. The current EV-to-EBIT is 25.65, which is 20% below median its 10-year median of 32.25 and 37.2% above the Medical Devices & Instruments industry median of 18.70. Convatec Group's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Convatec Group (CHIX:CTECL), the current EV-to-EBIT is 25.65 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Convatec Group (CHIX:CTECL) Overvalued in 2026?
Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued.
The current stock price of £2.28 is trading 11.2% below its estimated GF Value™ of £2.57.
GuruFocus considers Convatec Group to be Modestly Undervalued.
Key valuation signals for CHIX:CTECL:
EV-to-EBIT: 25.65 (20% below median its 10-year median of 32.25)
GF Value™: £2.57 vs. price of £2.28 (11.2% below fair value)
Industry Position: 37.2% above the Medical Devices & Instruments median (#317 of 468)
No single metric tells the full story. See the CHIX:CTECL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
78GF Score
Get the complete analysis for CHIX:CTECL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CTECL has been successfully added to your 
